Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

doi:10.1080/17512433.2023.2174523

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Expert review of clinical pharmacology - 1 Feb 2023

Solana-Altabella Antonio, Megías-Vericat Juan Eduardo, Ballesta-López Octavio, Martínez-Cuadrón David, Montesinos Pau

Abstract excerpt

INTRODUCTION: FLT3 inhibitors (FLT3i) are drugs in which there is limited experience and not yet enough information on the mechanisms of absorption, transport, and elimination; but especially on the potential drug-drug interactions (DDIs). There are therefore risks in the management of FLT3i DDIs (i.e. sorafenib, ponatinib, crenolanib, midostaurin, quizartinib, and gilteritinib) and ignoring them can compromise...

Topics

Humans
ATP Binding Cassette Transporter, Subfamily G, Member 2
Antineoplastic Agents
Neoplasm Proteins
Protein Kinase Inhibitors
Drug Interactions
Leukemia, Myeloid, Acute
fms-Like Tyrosine Kinase 3
Mutation

Source

Open in PubMed

Identifiers

PMID: 36708283
DOI: 10.1080/17512433.2023.2174523

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics